After some very public cajoling, executives from a number of the world’s largest drug makers have now agreed to testify about drug pricing at a Senate listening to later this month. They might be silly not to take action. The Senate Finance Committee management isn’t particularly pleasant to the pharmaceutical trade, which is already underneath siege. Exhibiting up is solely good politics within the face of proposals and laws that would change how they do enterprise.
In any case, President Trump publicly berated Pfizer final yr for taking a giant spherical of value hikes, and none of those executives want that type of aggravation. And momentum is constructing in Washington to do one thing about pricing. Now will not be the time to look detached and even mildly uncooperative.
However, I don’t assume merely agreeing to testify a assure of success, both. These executives know easy methods to behave earlier than Congress and cameras. They’ll sound cheap and knowledgeable, armed with lengthy lists of clean-as-silk speaking factors. And they’re going to work challenging to remain on message. Merck chief government Ken Frazier, as an illustration, is a talented lawyer who’s practiced within the artwork of finessing. At one level throughout his rise to the highest, he immediately oversaw the general public relations workers.